Loading data for CNSY — first visit, this takes a few seconds.
Cerenome, Inc. (CNSY)
NasdaqCM: CNSY
· Real-Time Price · USD
2.75
-0.23 (-7.72%)
At close: Sep 04, 2026, 8:00 PM
2.85
+3.52%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Cerenome, Inc. (CNSY) Stock Price, Analysis & Data
No data available
| Bid | 2.99 |
| Market Cap | 20.9M |
| Revenue (ttm) | 4.2M |
| Net Income (ttm) | -26.1M |
| 1.39 | |
| 2.93 | |
| 0.94 | |
| -1.15 | |
| P/B (ttm) | 3.69 |
| P/S (ttm) | 4.97 |
| Earnings Date | Mar 12, 2026 |
| Ask | 3.06 |
| Volume | 33,000 |
| Avg. Volume (20D) | 134,209 |
| Open | 2.89 |
| Previous Close | 2.98 |
| Day's Range | 2.74 - 2.97 |
| 52-Week Range | 2.62 - 23.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CNSY
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biode...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 11, 2001
Employees 28
Stock Exchange NasdaqCM
Ticker Symbol CNSY
Website https://cerenome.com
Financial Performance
In 2025, Cerenome's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -22.39M, an increase of 72.49%.
Financial StatementsEarnings Surprise
Cerenome has released their quarterly earnings on Aug 14, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.31 misses estimates by -0.43, with 90.76% YoY growth.
Cerenome, Inc. is scheduled to release its earnings on Mar 12, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade